LMAT
HealthcareLeMaitre Vascular, Inc. · Medical - Instruments & Supplies · $2B
What is LeMaitre Vascular, Inc.?
LeMaitre Vascular is a medical device company focused exclusively on peripheral vascular disease — a niche that sets it apart from broader surgical device makers. Headquartered in Burlington, Massachusetts, it serves surgeons and interventionists across global markets.
The company designs, markets, and supports a portfolio of specialty devices and implants used in vascular surgery. Revenue comes from direct sales forces and distributor networks spanning multiple countries. Its products address specific procedural needs — from removing blood clots to bypassing diseased arteries — giving it a focused commercial footprint in a specialized surgical segment rather than competing across the broader medical device landscape.
LeMaitre Vascular was incorporated in 2006 and is headquartered in Burlington, US.
- Embolectomy and thrombectomy catheters for clot removal
- Carotid shunts used during endarterectomy procedures
- Vascular grafts for bypassing or replacing diseased arteries
- Vascular and cardiac patches for vessel closure
- Valvulotomes and occlusion catheters for vascular intervention
Is LMAT a Good Stock to Buy?
UQS Score rates LMAT as Good overall, reflecting a balanced but not exceptional profile across the five quality pillars.
The Quality, Growth, and Risk pillars each carry Good ratings, suggesting the business generates reasonably consistent results, is expanding at a measured pace, and does not carry outsized financial or operational risk relative to its sector peers. These three pillars together form a stable foundation for a niche medical device operator.
The Moat pillar registers as Weak, indicating limited structural competitive advantages compared to larger device peers, while the Valuation pillar is rated Elevated — meaning the market may already be pricing in a favorable outlook.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LMAT pay dividends?
Yes — LeMaitre Vascular, Inc. pays a dividend.
LeMaitre Vascular pays a regular dividend, which is relatively uncommon among smaller medical device companies that typically reinvest all cash into growth. This signals a degree of financial confidence from management. Investors seeking income alongside exposure to the vascular surgery niche may find the dividend cadence meaningful, though the payout should be evaluated in the context of the Elevated Valuation rating.
When does LMAT report earnings?
LeMaitre Vascular reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Good Growth and Quality pillar ratings suggest results have been broadly constructive in recent periods, with revenue expanding and operational execution holding steady. Performance in niche surgical device markets can be lumpy quarter to quarter given procedure volumes and distributor timing.
For the most recent quarter's results and guidance, visit LeMaitre Vascular's investor relations page directly.
LMAT Price History
+128.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in LeMaitre Vascular, Inc.?
Based on LeMaitre Vascular, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
LMAT Long-term Outlook
The combination of Good Growth and Good Risk pillar ratings points to a business with a credible near-term expansion path and manageable downside exposure. However, the Weak Moat rating tempers longer-run confidence — without strong pricing power or switching costs, sustaining above-average growth may require continued product development and geographic expansion. The Elevated Valuation pillar suggests the current share price leaves limited margin of safety if execution stumbles.
Growth drivers
- Geographic expansion of direct sales force into underpenetrated international markets
- New product launches and line extensions within the peripheral vascular niche
- Aging global population increasing demand for vascular surgical procedures
Key risks
- Weak Moat rating signals vulnerability to competition from larger device makers
- Elevated Valuation leaves little room for earnings misses or guidance cuts
- Procedure volume sensitivity to hospital staffing and healthcare spending cycles
LMAT vs Peers
LeMaitre Vascular operates in a specialized corner of the medical device market, but investors often compare it to other healthcare device and equipment companies.
DENTSPLY SIRONA focuses on dental products and technologies, operating at a much larger scale across a different clinical specialty than LeMaitre's vascular surgery niche.
Haemonetics specializes in blood management solutions and transfusion technology, sharing a procedural healthcare focus but serving a distinct clinical workflow from vascular surgery.
Warby Parker is a consumer eyewear brand, representing a very different healthcare-adjacent business model built on direct-to-consumer retail rather than surgical device sales.
Frequently Asked Questions
What does LeMaitre Vascular do?
LeMaitre Vascular designs and sells specialty medical devices for peripheral vascular disease treatment. Its products — including catheters, grafts, patches, and shunts — are used by vascular surgeons during procedures to restore or manage blood flow. The company sells through both a direct sales force and distributor networks worldwide.
Does LMAT pay dividends?
Yes, LeMaitre Vascular pays a regular dividend. This is notable for a mid-cap medical device company, as many peers in the space reinvest all available cash into growth initiatives. Investors should review the current yield and payout history on the company's investor relations page.
When does LMAT report earnings?
LeMaitre Vascular follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source — check the company's investor relations page or a financial calendar service for the next scheduled report.
Is LMAT a good stock to buy?
UQS Score rates LMAT as Good overall. The Quality, Growth, and Risk pillars are each rated Good, while the Moat pillar is Weak and Valuation is Elevated. Whether that profile fits your portfolio depends on your own risk tolerance and investment goals. The full pillar breakdown is available to Pro members.
Is LMAT overvalued?
The UQS Valuation pillar for LMAT is rated Elevated, which indicates the stock is priced above what the underlying fundamentals alone might justify relative to sector peers. This does not mean the stock will decline, but it does suggest limited margin of safety at current levels.
How does LMAT compare to its competitors?
LeMaitre Vascular occupies a narrow niche within vascular surgery devices, which differentiates it from broader healthcare device companies. Peers like Haemonetics focus on blood management, while DENTSPLY SIRONA operates in dental care — different specialties with different growth and margin dynamics. See the competitor section above for more context.
What is LMAT's market cap bracket?
LeMaitre Vascular is classified as a mid-cap company. This places it in a range where institutional coverage exists but is less extensive than for large- or mega-cap peers, and liquidity can be more variable during periods of market stress.
Who founded LeMaitre Vascular?
LeMaitre Vascular was founded by George LeMaitre, whose family name the company bears. The founding context and leadership history are publicly available through the company's official filings and investor relations materials.
Is LMAT a long-term quality investment?
From a quality-indicator perspective, LMAT's Good ratings across Quality, Growth, and Risk pillars suggest a business with reasonable durability. The Weak Moat rating is worth monitoring over a longer horizon, as competitive advantages are a key driver of sustained returns. Pro members can view the complete long-term quality analysis.
What is the main competitive advantage of LeMaitre Vascular?
LeMaitre's primary edge comes from its deep specialization in peripheral vascular surgery — a niche where relationships with vascular surgeons and a broad procedural product portfolio create switching friction. However, the UQS Moat pillar rates this advantage as Weak relative to the broader healthcare device sector.
What sector does LMAT belong to?
LeMaitre Vascular is classified in the Healthcare sector, specifically within medical devices and implants. It serves a surgical subspecialty — peripheral vascular disease — rather than competing across the full medical device landscape.
Unlock Full LMAT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores for all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare LMAT against sector peers side by side
- ✓See the full valuation and risk deep-dive
- ✓Get updated scores each quarter after earnings
- ✓Explore screener presets built around quality factors
Pro Analysis
LMAT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 17, 2026 | 58.5 | 69.1 | 39.0 | 69.4 | 73.6 | 43.9 | +2.4 |
| May 7, 2026 | 56.1 | 66.2 | 39.0 | 67.0 | 71.9 | 37.5 | +0.1 |
| May 3, 2026 | 56.0 | 66.2 | 39.0 | 67.0 | 71.9 | 36.8 | +0.1 |
| Apr 26, 2026 | 55.9 | 66.2 | 39.0 | 67.0 | 71.9 | 36.3 | 0.0 |
| Apr 19, 2026 | 55.9 | 66.2 | 39.0 | 67.0 | 71.9 | 36.0 | 0.0 |
| Apr 18, 2026 | 55.9 | 66.2 | 39.0 | 67.0 | 71.9 | 35.9 | -1.3 |
| Apr 12, 2026 | 57.2 | 66.2 | 39.0 | 67.0 | 71.9 | 44.9 | -0.4 |
| Apr 10, 2026 | 57.6 | 66.3 | 39.0 | 67.0 | 71.9 | 47.6 | +0.3 |
| Apr 9, 2026 | 57.3 | 66.3 | 39.0 | 65.9 | 71.9 | 46.8 | 0.0 |
| Apr 7, 2026 | 57.3 | 66.5 | 39.0 | 65.9 | 71.9 | 46.8 | -0.1 |
LMAT — Pillar Breakdown
Quality
— 69.0/100 (25%)LeMaitre Vascular, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 69.4/100 (20%)LeMaitre Vascular, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 73.6/100 (15%)LeMaitre Vascular, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 43.8/100 (15%)LeMaitre Vascular, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 39/100 (25%)LeMaitre Vascular, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LMAT.
Score Composition
Financial Data
More Stock Analysis
How is the LMAT UQS Score Calculated?
The UQS (Unified Quality Score) for LeMaitre Vascular, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses LeMaitre Vascular, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether LeMaitre Vascular, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.